management system. Electronic comments or submissions will be accepted by FDA only through FDMS at *http://www.regulations.gov*.

IV. References

The following references have been placed on display in the Division of Dockets Management (see **ADDRESSES**) and may be seen by interested persons between 9 a.m. and 4 p.m., Monday through Friday. (FDA has verified the Web site addresses, but FDA is not responsible for any subsequent changes to the Web sites after this document publishes in the **Federal Register**.)

1. Sivapalasingam, S., et al. ''Fresh Produce: A Growing Cause of Outbreaks of Foodborne Illness in the United States, 1973 through 1997,'' *Journal of Food Protection* 67(10): 2342–53, 2004.

2. U.S. Food and Drug Administration, 1996 to 2007 Produce Outbreaks (unpublished compilation).

3. U.S. Food and Drug Administration, ''Guide to Minimize Microbial Food Safety Hazards for Fresh Fruits and Vegetables,'' October 26, 1998, available at *http://www.cfsan.fda.gov/~dms/prodguid.html*.

4. U.S. Food and Drug Administration, ''Produce Safety From Production to Consumption: 2004 Action Plan to Minimize Foodborne Illness Associated with Fresh Produce Consumption,'' October 2004, available at *http://www.cfsan.fda.gov/~dms/prodpla2.html*.

5. U.S. Food and Drug Administration, ''Leafy Greens Safety Initiative—2nd year,'' October 4, 2007, available at *http://www.cfsan.fda.gov/~dms/lettsaf2.html*.

6. U.S. Food and Drug Administration, ''Tomato Safety Initiative,'' June 12, 2007, available at *http://www.cfsan.fda.gov/~dms/tomsafe.html*.

7. ''Safety of Fresh Produce; Public Hearings; Request for Comments'' (72 FR 8750, February 27, 2007), Public hearings held on March 20, 2007, and April 13, 2007, *http://www.regulations.gov/fdmspublic/component/main?main=DocketDetail&d=FDA–2007–N–0380*.

8. California Leafy Green Products Handler Marketing Agreement, available at *http://www.caleafygreens.ca.gov*.

II. Electronic Access

Persons with access to the Internet may obtain the document at *http://www.cfsan.fda.gov/~dms/prodguid.html*.

Dated: August 19, 2008.

Jeffrey Shuren,

Associate Commissioner for Policy and Planning.

[FR Doc. E8–20187 Filed 8–29–08; 8:45 am]

BILLING CODE 4160–01–S

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

[Docket No. FDA–2008–N–0466]

Over the Counter Cough and Cold Medication for Pediatric Use; Notice of Public Hearing; Correction

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice of public hearing; request for comments; correction.

SUMMARY: The Food and Drug Administration is correcting a notice that published in the **Federal Register** on August 25, 2008 (73 FR 50033). The notice announced a public hearing to obtain input regarding over-the-counter (OTC) cough and cold drugs marketed for pediatric use. Due to some confusion regarding electronic registration, this notice revises the electronic registration procedures, and corrects the address for the contact person.

DATES: The correction is effective September 2, 2008.

FOR FURTHER INFORMATION CONTACT: Faith Dugan, Food and Drug Administration, 10903 New Hampshire Ave., rm. 6182, Silver Spring, MD 20993, 301–796–3446, Faith.Dugan@fda.hhs.gov.

SUPPLEMENTARY INFORMATION: In FR Doc. E8–19657, published on August 25, 2008 (73 FR 50033), the following correction is made to **ADDRESSES**:

1. On page 50033, in the first and second columns, the **ADDRESSES** section is corrected to read as follows:

ADDRESSES: Submit written comments to the Division of Dockets Management (HFA–305), Food and Drug Administration, 5630 Fishers Lane, rm. 1061, Rockville, MD 20852.

E-mail electronic registration to: Faith.Dugan@fda.hhs.gov. Anyone who has already registered via *http://www.regulations.gov* does not have to re-register. The agency will accept those registrations.

Submit electronic comments to *http://www.regulations.gov*. All comments should be identified with the docket number found in brackets in the heading of this document.

Transcripts of the hearing will be available for review at the Division of Dockets Management and on the Internet at *http://www.regulations.gov* approximately 30 days after the hearing.

For Registration to Attend and/or Participate in the Hearing: Seating at the hearing is limited. People interested in attending should submit electronic registration to Faith Dugan by close of business on September 15, 2008. Registration is free and will be on a first-come, first-served basis. Written or electronic comments will be accepted until December 2, 2008.

If you wish to make an oral presentation at the hearing, you must state your intention on your registration submission (see **ADDRESSES**). To speak, submit your name, title, business affiliation, address, telephone and fax numbers, and e-mail address. FDA has included questions for comment in section II of this document. You should also identify by number each question you wish to address in your presentation. FDA will do its best to accommodate requests to speak. Individuals and organizations with common interests are urged to consolidate or coordinate their presentations, and to request time for a joint presentation. FDA will determine the amount of time allotted to each presenter and the approximate time that each oral presentation is scheduled to begin.

If you need special accommodations because of a disability, please inform Faith Dugan, (see For Information on the Hearing Contact).

For Information on the Hearing Contact: Faith Dugan, Food and Drug Administration, 10903 New Hampshire Ave., rm. 6182, Silver Spring, MD 20993 , 301–796–3446, FAX: 301–847–4752, e-mail: Faith.Dugan@fda.hhs.gov.

Dated: August 27, 2008.

Jeffrey Shuren,

Associate Commissioner for Policy and Planning.

[FR Doc. E8–20370 Filed 8–28–08; 11:15 am]

BILLING CODE 4160–01–S

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

National Institute of Neurological Disorders and Stroke; Notice of Closed Meeting

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. Appendix 2), notice is hereby given of the following meeting.

The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant